Background. Gastric cancer is more frequently diagnosed at an advanced stage; in Ukraine, nearly 60% of patients have stage III or IV disease at the time of diagnosis, when surgical treatment is either inappropriate or not feasible. Conventional chemotherapy provides only limited improvement in survival; therefore, interest in targeted therapy and immunotherapy as promising treatment modalities is increasing. Purpose – was to present the results of histological, immunohistochemical, and molecular genetic characteristics of gastric cancer and the tumor microenvironment as predictors of prognosis and selection of systemic medical treatment. Materials and Methods. Data retrieval for the review was conducted in accordance with the PRISMA-ScR guidelines. A systematic search was performed in PubMed, Scopus, Google Scholar, and Embase (from 2017 to the present) and was supplemented by a review of major clinical guidelines (NCCN, ESMO) published over the past five years. Results. The results of the literature search over the past ten years demonstrated that an integrated assessment of histological and immunohistochemical characteristics enables more accurate classification of gastric cancer, prediction of its biological aggressiveness, and selection of individualized therapeutic approaches. Moreover, morphological analysis of the tumor – stroma ratio at the invasive front allows for a more precise interpretation of the clinical significance of the tumor microenvironment (TME) and facilitates the identification of novel prognostic markers associated with gastric cancer progression. Molecular genetic characteristics of the tumor (HER2 status, PD-L1 expression [CPS], MSI/MMR status, EBV positivity, and CLDN18.2 expression) determine the feasibility of personalized therapy. In metastatic gastric cancer, the integration of molecular profiling with TME characteristics enables a rational choice among anti-HER2 strategies, antiangiogenic therapy, immunotherapy, or their combinations. Conclusions. Comprehensive characterization of the tumor microenvironment, along with the immunohistochemical and molecular genetic landscape of the tumor stage IVa,b gastric cancer, should become a standard of clinical practice to enable personalized systemic therapy and improve survival outcomes.